Zobrazeno 1 - 10
of 113
pro vyhledávání: '"Juan Carlos, Laguna"'
Autor:
Juan Carlos Laguna, Miguel García-Pardo, Joao Alessi, Carlos Barrios, Navneet Singh, Humaid O. Al-Shamsi, Herbert Loong, Miquel Ferriol, Gonzalo Recondo, Laura Mezquita
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Lung cancer poses a global health challenge and stands as the leading cause of cancer-related deaths worldwide. However, its incidence, mortality, and characteristics are not uniform across all regions worldwide. Understanding the factors contributin
Externí odkaz:
https://doaj.org/article/e7e80dee28a84ad0826987713fd09406
Autor:
Benedetta Di Veroli, Roger Bentanachs, Núria Roglans, Marta Alegret, Letizia Giona, Elisabetta Profumo, Alessandra Berry, Luciano Saso, Juan Carlos Laguna, Brigitta Buttari
Publikováno v:
Cells, Vol 13, Iss 15, p 1247 (2024)
Sex differences may play a role in the etiopathogenesis and severity of metabolic dysfunction-associated steatotic liver disease (MASLD), a disorder characterized by excessive fat accumulation associated with increased inflammation and oxidative stre
Externí odkaz:
https://doaj.org/article/b0fbd2a3d6024cabbbb7802811c6b8d8
Autor:
Marta García de Herreros, Juan Carlos Laguna, Joan Padrosa, Tanny Daniela Barreto, Manoli Chicote, Carme Font, Ignacio Grafiá, Lucía Llavata, Elia Seguí, Albert Tuca, Margarita Viladot, Carles Zamora-Martínez, Sara Fernández-Méndez, Adrián Téllez, Josep Maria Nicolás, Aleix Prat, Pedro Castro-Rebollo, Javier Marco-Hernández
Publikováno v:
Diagnostics, Vol 14, Iss 7, p 730 (2024)
Background: Despite the increasing number of ICU admissions among patients with solid tumours, there is a lack of tools with which to identify patients who may benefit from critical support. We aim to characterize the clinical profile and outcomes of
Externí odkaz:
https://doaj.org/article/91c39e44da654bef8ae8199d15523abb
Autor:
Ignacio Grafia, Mariana Chumbita, Elia Seguí, Celia Cardozo, Juan Carlos Laguna, Marta García de Herreros, Nicole Garcia-Pouton, Ana Villaescusa, Cristina Pitart, Verónica Rico-Caballero, Javier Marco-Hernández, Carles Zamora, Margarita Viladot, Joan Padrosa, Albert Tuca, Eric Mayor-Vázquez, Francesc Marco, Jose A. Martínez, Josep Mensa, Carolina Garcia-Vidal, Alex Soriano, Pedro Puerta-Alcalde
Publikováno v:
Microbiology Spectrum, Vol 11, Iss 5 (2023)
ABSTRACT We aimed to describe the characteristics and outcomes of biliary source bloodstream infections (BSIs) in oncological patients. Secondarily, we analyzed risk factors for recurrent BSI episodes. All episodes of biliary source BSIs in oncologic
Externí odkaz:
https://doaj.org/article/4065fa5a80614eebad5a6e6b21b213fc
Autor:
Nuria Roglans, Miguel Baena, Gemma Sangüesa, Ana Magdalena Velázquez, Christian Griñán-Ferré, Mercè Pallàs, Rosa María Sánchez, Marta Alegret, Juan Carlos Laguna
Publikováno v:
Food & Nutrition Research, Vol 65, Pp 1-15 (2021)
Background: Non-alcoholic fatty liver disease (NAFLD) has increased over the last decades and may evolve into hepatocellular carcinoma (HCC). As HCC is challenging to treat, knowledge on the modifiable risk factors for NAFLD/HCC (e.g. hyper caloric d
Externí odkaz:
https://doaj.org/article/f1c37e51f156493784fda254eeeaf8d5
Autor:
Víctor Albarrán-Artahona, Juan-Carlos Laguna, Teresa Gorría, Javier Torres-Jiménez, Mariona Pascal, Laura Mezquita
Publikováno v:
Diagnostics, Vol 12, Iss 9, p 2091 (2022)
Immunotherapy has dramatically changed the therapeutic landscape of oncology, and has become standard of care in multiple cancer types in front or late lines of therapy, with some longstanding responses and outstanding results. Notwithstanding, its u
Externí odkaz:
https://doaj.org/article/d54bdb7b98ff4fa1954355333c7de9d4
Autor:
Ana Magdalena Velázquez, Roger Bentanachs, Aleix Sala-Vila, Iolanda Lázaro, Jose Rodríguez-Morató, Rosa María Sánchez, Juan Carlos Laguna, Núria Roglans, Marta Alegret
Publikováno v:
Biomedicines, Vol 10, Iss 7, p 1517 (2022)
Bempedoic acid (BemA) is an ATP-citrate lyase (ACLY) inhibitor used to treat hypercholesterolemia. We studied the anti-steatotic effect of BemA, and the mechanisms involved, in a model of fatty liver in female rats obtained through the administration
Externí odkaz:
https://doaj.org/article/4a40e317c75a44f4878f7270f8c3a005
Publikováno v:
Clínica e Investigación en Arteriosclerosis.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4579aeff887d72598363fad94ae724c
https://doi.org/10.1016/j.arteri.2023.05.001
https://doi.org/10.1016/j.arteri.2023.05.001
Publikováno v:
Current Opinion in Lipidology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::380447373dcaef43c62d8aa0e7db20b9
https://doi.org/10.1097/mol.0000000000000878
https://doi.org/10.1097/mol.0000000000000878
Autor:
Roger, Bentanachs, Ana Magdalena, Velázquez, Rosa María, Sánchez, Marta, Alegret, Juan Carlos, Laguna, Núria, Roglans
Publikováno v:
Clínica e Investigación en Arteriosclerosis (English Edition). 34:57-67
In its initial stages, nonalcoholic fatty liver disease presents hypertriglyceridemia and accumulation of lipids in the liver (hepatic steatosis). Bempedoic acid is an ATP:citrate lyase inhibitor that promotes a dual inhibition of the synthesis of ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0a90d04f3757a22b938c632df5bb44f
https://doi.org/10.1016/j.artere.2022.03.001
https://doi.org/10.1016/j.artere.2022.03.001